A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Adult Subjects with Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 05 May 2017
At a glance
- Drugs MEDI 0639 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors MedImmune
- 07 Jun 2016 Results of a sub-group analysis from patients with small-cell lung cancer (n=9) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 27 Apr 2016 Status changed from recruiting to completed.
- 06 Aug 2015 Planned End Date changed from 1 Nov 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.